David T. Scadden, MD, is a scientific founder of Clear Creek Bio and a member of the board. He is the Gerald and Darlene Jordan Professor of Medicine at Harvard University and Professor and Chair emeritus of the Harvard University Department of Stem Cell and Regenerative Biology. David co-founded and co-directs the Harvard Stem Cell Institute with Douglas Melton. He is a hematologist/oncologist at the Massachusetts General Hospital where he founded and directs the Center for Regenerative Medicine and previously led the Hematologic Malignancies Program of the MGH Cancer Center.
He is a member or fellow of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Association for the Advancement of Science, the American College of Physicians, and a former member of the Board of External Experts for the National Heart, Lung, and Blood Institute and the National Cancer Institute’s Board of Scientific Counselors. He is an Affiliate Member of the Broad Institute of Harvard and MIT. David co-founded Fate Therapeutics and Magenta Therapeutics and is a Director of Agios Pharmaceuticals.
David is motivated to translate potentially life-saving innovations from the bench into novel therapies for blood diseases. His vision for Clear Creek Bio, and motivation for his naming it, is that its therapies could pro-differentiate and clear the blood of cancer cells.